COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1

被引：1
|
作者：
Smolen, J. S. [1 ]
Lubrano, E. [2 ]
Kishimoto, M. [3 ]
Balanescu, A. [4 ]
Strand, V. [5 ]
Gao, T. [6 ]
Vranich, N. [6 ]
Lippe, R. [7 ]
Tillett, W. [8 ]
机构：
[1] Med Univ Vienna, Med, Vienna, Austria
[2] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy
[3] Kyorin Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[4] Carol Davila Univ Med & Pharm, Dept Internal Med & Rheumatol, St Maria Hosp, Bucharest, Romania
[5] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA
[6] AbbVie Inc, Immunol, N Chicago, IL USA
[7] AbbVie Deutschland GmbH & Co KG, Immunol, Wiesbaden, Germany
[8] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1279
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1025
引用
收藏
页码：824 / 824
页数：1
相关论文
共 50 条
  • [21] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Chen, L.
    Duan, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 260 - 261
  • [22] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Li, Y.
    Liu, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1137 - 1138
  • [23] Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
    McInnes, Iain B.
    Kato, Koji
    Magrey, Marina
    Merola, Joseph F.
    Kishimoto, Mitsumasa
    Pacheco-Tena, Cesar
    Haaland, Derek
    Chen, Liang
    Duan, Yuanyuan
    Zueger, Patrick
    Liu, John
    Lippe, Ralph
    Pangan, Aileen L.
    Behrens, Franck
    RMD OPEN, 2021, 7 (03):
  • [24] UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Lertratanakul, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Dokoupilova, E.
    Keiserman, M.
    Bu, X.
    Chen, L.
    Mccaskill, R.
    Zueger, P.
    Mcdearmon-Blondell, E.
    Pangan, A.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 312 - 314
  • [25] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
    Mease, Philip J.
    Assad, Rodrigo Luppino
    Tsuji, Shigeyoshi
    Richette, Pascal
    Setty, Arathi
    McDearmon-Blondell, Erin
    Gao, Tianming
    Ciecinski, Sandra
    Van den Bosch, Filip
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4258 - 4261
  • [26] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Mease, Philip J.
    Lertratanakul, Apinya
    Papp, Kim A.
    van den Bosch, Filip E.
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro W.
    Bu, Xianwei
    Chen, Liang
    McCaskill, Reva M.
    Zueger, Patrick
    McDearmon-Blondell, Erin L.
    Pangan, Aileen L.
    Tillett, William
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 903 - 919
  • [27] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Carter, K.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1136 - 1137
  • [28] Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
    Philip J. Mease
    Apinya Lertratanakul
    Kim A. Papp
    Filip E. van den Bosch
    Shigeyoshi Tsuji
    Eva Dokoupilova
    Mauro W. Keiserman
    Xianwei Bu
    Liang Chen
    Reva M. McCaskill
    Patrick Zueger
    Erin L. McDearmon-Blondell
    Aileen L. Pangan
    William Tillett
    Rheumatology and Therapy, 2021, 8 : 903 - 919
  • [29] IMPACT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK IN PATIENTS TREATED WITH UPADACITINIB VERSUS COMPARATORS: POST HOC ANALYSIS OF THE SELECT RHEUMATOID ARTHRITIS PROGRAM
    Charles-Schoeman, C.
    Buch, M. H.
    Burmester, G. R.
    Liu, J.
    Dilley, D.
    Palac, H.
    Strengholt, S.
    Curtis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 711 - 712
  • [30] ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES
    Kavanaugh, A.
    Mease, P. J.
    Douglas, K.
    Behrens, F.
    Haaland, D.
    Palominos, P.
    Lertratanakul, A.
    Lane, M.
    Lippe, R.
    Aletaha, D.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1306 - 1307
12345